John DeFord - Sep 1, 2023 Form 4 Insider Report for NUVASIVE INC (NUVA)

Role
Director
Signature
/s/ Nathaniel B. Sisitsky, Attorney-in-Fact for John A. DeFord
Stock symbol
NUVA
Transactions as of
Sep 1, 2023
Transactions value $
$0
Form type
4
Date filed
9/5/2023, 04:40 PM
Previous filing
Aug 1, 2023
Next filing
Nov 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -563 -100% $0.00* 0 Sep 1, 2023 Common Stock 563 Direct F1, F2
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -3.23K -100% $0.00* 0 Sep 1, 2023 Common Stock 3.23K Direct F1, F2
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -2.58K -100% $0.00* 0 Sep 1, 2023 Common Stock 2.58K Direct F1, F2
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -3.1K -100% $0.00* 0 Sep 1, 2023 Common Stock 3.1K Direct F1, F2
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -2.7K -100% $0.00* 0 Sep 1, 2023 Common Stock 2.7K Direct F1, F2
transaction NUVA Restricted Stock Disposed to Issuer $0 -3.79K -100% $0.00* 0 Sep 1, 2023 Common Stock 3.79K Direct F1, F2
transaction NUVA Restricted Stock Unit Disposed to Issuer $0 -4.82K -100% $0.00* 0 Sep 1, 2023 Common Stock 4.82K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John DeFord is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represented a contingent right to receive one share of the Issuer's common stock upon vesting.
F2 Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.